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Silent Tragedy
Gamal Shiha and Nasser Mousa
Abstract
Hepatic encephalopathy (HE) is brain dysfunction caused by both acute and 
chronic liver diseases that produces a spectrum of neuropsychiatric symptoms in 
the absence of other known brain diseases. Minimal hepatic encephalopathy (MHE) 
is the mildest form of this spectrum. MHE is defined as HE without symptoms 
on clinical or neurological examination, but with deficits in the performance of 
psychometric tests, working memory, psychomotor speed, and visuospatial abil-
ity. Minimal hepatic encephalopathy is associated with impaired driving skills and 
increased risk of motor vehicle accidents and has been associated with increased 
hospitalizations and death. Despite its clinical importance, a large number of 
clinicians had never investigated whether their cirrhotic patients might have 
MHE. Although, there is no single gold standard test for diagnosis of MHE, a 
combination of two neuropsychological tests or psychometric hepatic encepha-
lopathy score battery test and/or neurophysiological test is standard for diagnosis 
of MHE. It was found that, treatment for MHE improves neuropsychiatric perfor-
mance and quality of life and decreases the risk of developing overt HE (OHE). 
The agents used to treat OHE have been tested in patients with MHE. In particular, 
lactulose, rifaximin, probiotics and l-ornithine and l-aspartate (LOLA) have all 
been shown to be beneficial, with documented improvement in psychometric 
performance after treatment.
Keywords: liver cirrhosis, hepatic encephalopathy, minimal hepatic encephalopathy, 
ammonia, neuropsychological testing, motor vehicle accident, lactulose and rifaximin
1. Introduction
Hepatic encephalopathy (HE) is a serious clinical problem of portal hyper-
tension and cirrhosis that is characterized by neurologic and neuropsychiatric 
abnormalities. It is manifested by personality changes, cognitive dysfunction, and 
altered level of consciousness [1, 2]. Based on the severity, HE is classified into two 
groups: overt HE (OHE) presents episodically or continuously with obvious and 
clinically detectable symptoms; in contrast, covert HE (CHE) combines the two 
lowest grades of HE (minimal HE (MHE) and HE grade 1) [3]. Therefore, under the 
new classification (Table 1), OHE starts with grade 2 or with evidence of asterixis 
and disorientation. MHE is characterized by subtle cognitive and psychomotor 
deficits in the absence of recognizable clinical symptoms and signs of HE and is 
documented by neuropsychometric (NP) tests and neurophysiological tests, but HE 
grade 1 is defined by the presence of mild clinical alterations like euphoria, anxiety, 
or a shortened attention span. Although the consequences are serious, mostly CHE 
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is often unnoticed or even neglected in routine clinical practice due to only very 
mild symptoms associated with grade 1, or no diagnostics in case of MHE [4, 5].
Minimal hepatic encephalopathy may have a bad impact on quality of life, risk of 
road traffic accidents, and can progress to overt HE [6, 7]. Still, there are no cur-
rent guidelines for the ascertained diagnosis of MHE. The Working Group on HE 
endorsed that, at least two of the following neuropsychologic tests should be used 
for diagnosing MHE: number connection test-A (NCT-A), NCT-B, block-design 
test (BDT), and the digit-symbol test (DST) [4]. The existing definition of MHE 
is built on psychometric test results that are two SDs more than normal on at least 
two psychometric tests [8]. Therapy for MHE is targeted toward the gut, due to 
the ammoniagenic role of the gut contents, which have been hypothesized to play a 
part in MHE pathogenesis. Guidelines for HE in chronic liver disease do not recom-
mend routine treatment of MHE. However, they state that when a patient has clear 
cognitive impairment, or deterioration of quality of life (QoL), skills for driving, 
or ability to perform jobs that require manual labor or have high public risk, the 
patient should be treated [3, 9].
2. Prevalence of MHE
MHE is considered as a part of wide spectrum of typical neurocognitive altera-
tions in liver cirrhosis, mostly involving the areas of attention, alertness, response 
inhibition, and executive functions [10, 11]. Depending on the population studied, 
patient level of education, age of the patients, and the diagnostic tool used, MHE 
incidence varies from 20 to 80% of cirrhotic patients [12–15].
3. Physiopathology
The pathogenesis of MHE is nearly similar to that of OHE [16]. The ammonia 
toxicity remains the key factor, but recently there is increased evidence that, 
hyperammonemia acts synergistically with systemic inflammation, oxidative 
stress, and gut microbiota [17, 18]. Numerous investigators suggested that, hepatic 
encephalopathy is a disorder of astrocyte function that plays a role in the detoxifi-
cation of ammonia [19].
Classification Covert HE Overt HE
MHE Grade I Grade II Grade III Grade IV
Description * Absence of 
recognizable clinical 
symptoms and signs
* Impairments only 
measurable with 
psychometric tests 
(psychomotor speed/
executive functions 
or neurophysiological 
alterations)
* Minor 
lack of 
awareness
* Euphoria 
or anxiety
* Shortened 
attention 
span
* Altered 
sleep 
rhythm
* Fatigue, 
apathy, or 
lethargy
* Slight 
disorientation 
for time and 
place
* Obvious 
personality 
change
* Inappropriate 
behavior
* Asterixis
* Somnolence to 
semi-stupor
* Confused
* Marked 
disorientation to 
time and place
*Aggression
* Coma
* Signs of 
increased 
intracranial 
pressure
Table 1. 
New classification combining covert and overt HE.
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3.1 The role of ammonia
Ammonia is a key intermediate product in the metabolism of proteins. It is 
manufactured by the bacterial metabolism of amino acids and purines that are 
consumed in the human diet [20]. Under physiological environment, about 90% 
of the ammonium is primarily cleared by the synthesis of urea in the liver (by the 
Krebs cycle) and subsequently cleared by the kidneys and to a lesser extent by the 
muscles (Figure 1). Ammonia is also consumed in the conversion of glutamate 
to glutamine, a reaction that depends upon the activity of glutamine synthetase 
[21]. In liver cirrhosis, there are two factors that contribute to hyperammonemia: 
the first is a decrease in the healthy hepatocytes, resulting in deficiency of NH3 
detoxification; the second is the existence of porto-systemic shunting that results 
in shifting of NH3-rich portal blood to the systemic circulation without hepatic 
detoxification—subsequently, the extrahepatic metabolization of ammonia by the 
brain and skeletal muscle cells becomes more important [17, 22, 23]. The skeletal 
muscle plays a significant role in ammonia metabolism as it contains glutamine 
synthetase. However, the muscle wasting that is clear in advanced cirrhosis may 
increase hyperammonemia. The kidneys express glutaminase and, somewhat, play 
a role in ammonia production. Similarly, the kidneys express glutamine synthetase 
and play a key role in ammonia metabolism and excretion [20]. Ammonia crosses 
the blood-brain barrier and is metabolized in the astrocytes by glutamine synthe-
tase, which converts NH3 and glutamate to glutamine [17]. Increasing glutamine 
in astrocytes produces an osmotic gradient (Figure 2), promotes water shift 
into astrocyte producing edema [23], and generation of reactive oxygen species, 
Figure 1. 
Ammonia is produced primarily in colon from breakdown of amino acids and urea by bacteria. The ammonia 
is taken up by hepatocytes and converted, in the urea cycle, to urea, which is passed into blood. Urea is 
primarily excreted in the kidneys (75%) and the intestine (around 25%).
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thereby contributing to the cerebral dysfunction seen in HE [17]. The high-energy 
consumption by this process leads to oxidative stress which is accompanied by 
cellular dysfunction and disruption of neurotransmission predominantly of 
glutamate and γ-aminobutyric acid [24]. In the brain, NH3 produces inactivation 
of neuronal chloride extrusion pumps; these processes result in inhibition of both 
axonal conduction and excitatory postsynaptic potentials, subsequently suppress-
ing inhibitory postsynaptic potential formation and depolarizing neurons [25, 26].
3.2 Inflammation
Studies demonstrated that, severity of MHE might not correlate with severity of 
liver disease or the level of ammonia, proposing the existence of other pathogenic 
Figure 2. 
Pathogenesis of hepatic encephalopathy. In normal conditions, gut release of ammonia results in high portal 
vein ammonia levels. Microbiota is also responsible for the formation of ammonia, endotoxins. In liver 
cirrhosis, the liver extracts portal venous ammonia poorly. The subsequent increase of arterial ammonia levels 
leads to increased disposition of ammonia in other tissues. Both the brain and muscle lack a complete urea cycle 
and rely on the formation of glutamine. Thus, the brain and muscle become ammonia-uptake and glutamine-
releasing organs. In the brain, astrocytes metabolize ammonia through glutamine synthetase, converting 
glutamate and ammonia to glutamine which is osmotically active and promotes water shift into the astrocyte, 
thus producing intracellular swelling and edema.
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stimuli. Inflammation is one such stimulus that may add to the advancement of MHE 
and its progression to overt HE [27]. The studies suggested that, inflammation plays a 
synergistic role with ammonia in producing and modulating MHE [27–29]. Studies in 
patients with cirrhosis have documented higher levels of proinflammatory cytokines 
like tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6. This reflects the 
possibility of developing a systemic inflammatory response that alters the blood-brain 
barrier (BBB) permeability and allows diffusion of ammonia moreover [30, 31].
3.3 Microbiota
Studies suggested that, many interactions with gut microbiota can play an 
active role in MHE (Figure 2). Microbiota changes have been linked with impaired 
cognition, endotoxemia, and inflammation. With the progression of cirrhosis, 
there is dysbiosis (unfavorable change in the composition of the microbiome) 
with decreased levels of autochthonous taxa (native Firmicutes) bacteria and 
increased levels of other taxa (Bacteroidetes, Actinobacteria). The native bacteria 
are important for the harmony of the gastrointestinal flora and for the well-being 
of the entire body. The autochthonous bacteria produce short-chain fatty acids that 
feed the colonic mucosal cells and reduce local colonic inflammation, and produce 
anti-bacterial peptides [32]. In patients with minimal HE, stool microbiota studies 
demonstrated an increase in Streptococcus salivarius [33]. Zhang et al. found worse 
dysbiosis in all cirrhotic patients versus healthy controls and also found over-
representation of two bacterial families, Streptococcaceae and Veillonellaceae, in 
cirrhotic patients with and without MHE as compared with controls. Moreover, 
patients with MHE had an overabundance of Streptococcus salivarius. This dysbiosis 
could increase ammonia production due to its urease activity, and its count posi-
tively correlated with ammonia levels and cognitive testing in patients with MHE 
[34]. The cirrhosis dysbiosis ratio (CDR) is the ratio of autochthonous to non-
autochthonous taxa in cirrhosis. The lower the CDR the more the endotoxemia and 
more decompensated the cirrhosis [35].
4. Natural history of MHE
The incidence of MHE increases with progression of liver disease. With time, 
MHE may improve or progress to OHE [36, 37]. The rate of progression to overt HE 
was much higher in patients with MHE and Child-Pugh score > 6 than in those with 
MHE and Child-Pugh score ≤ 6 [38]. Moreover, MHE in patients with large portal-
systemic shunts had a better outcome due to preserved hepatocytes [39]. Real 
probability of OHE at 3 years was 56% in patients of liver cirrhosis in the presence 
of MHE and 8% for those without MHE [37]. In addition, existence of MHE in cir-
rhosis associated with shorter survival time and increased mortality rate compared 
to those without MHE [40–43].
5. Clinical significance
MHE has a significant impact on daily activities. It decreases patients’ quality 
of life (QoL) [43, 44] and driving impairment due to the attention and visuomotor 
coordination deficits [45–47]. The Sickness Impact Profile was studied in a group of 
patients with cirrhosis to evaluate QoL indicators such as sleep, rest, eating, work, 
home management, recreation, ambulation, daily care, movement, and emotional 
behavior. All scales were significantly decreased in patients with MHE compared 
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with individuals without MHE [48]. Moreover, those patients suffer from falls [49] 
and have a high risk of development of episodic HE [2].
5.1 Health-related quality of life (HRQoL)
Quality of life is a multidimensional index that reports all aspects of human 
well-being, including physical and cognitive capabilities, functional behavior, 
emotional status, and psychosocial adjustment [50]. The American Association 
for the Study of Liver Diseases survey conducted in 2007 demonstrated that, 
most clinicians believe MHE to be a significant problem. However, only 50% of 
clinicians had examined whether their patients might have MHE, and 38% had 
never studied their patients with liver cirrhosis [51]. Several evidences show 
that, HRQoL may seem to be influenced by the coexistence of MHE [48, 52–56]. 
MHE increases the incidence of disability, and has a negative effect on daily 
activities. The impact of the perception of the disease, in the form of a “Sickness 
Impact Profile,” has been studied in cirrhotic patients to assess the indicators of 
QoL. Each profile was significantly reduced in patients with MHE compared to 
individuals without MHE [48]. In addition, in the presence of MHE, QoL indica-
tors, such as the capacity to drive a car, and the incidence of sleep disorders were 
also negatively affected [57, 58].
5.2 MHE and falls
Minimal hepatic encephalopathy is significantly associated with high risk of falls 
explaining the increased healthcare and hospitalization rate in patients with MHE 
compared to cirrhotic patients without MHE [49, 59, 60]. The presence of cognitive 
impairment was the only independent factor predictive of a fall. The chance of a 
fall in 1 year was found to be significantly higher in patients with MHE compared to 
those without MHE. Urios et al. demonstrated that, MHE patients show impaired 
balance, mainly on an unstable surface with eyes open, with longer reaction and 
confinement times and lower success in stability test limits compared to patients 
without MHE [61].
5.3 Effect of MHE on driving
Traffic accidents are more common in patients with MHE compared to normal 
individuals, as the driving process in patients with MHE is affected by defects in 
many factors such as, defects in attention and information processing, slow reac-
tions, improper estimation of traffic conditions, and lack of coordination [48, 62]. 
As many as 33% of MHE patients reported a traffic accident or violation within the 
past year [63]. Interestingly, treatment with lactulose could substantially reduce 
societal costs by preventing motor vehicle accidents [64].
5.4 Risk of overt HE
MHE has been found to predict the development of overt HE in cirrhotic 
patients [2]. A recent study demonstrated that, CHE and elevated blood NH3 levels 
contributed to OHE development in cirrhotic patients [65]. The results of Wang 
et al. showed that, solely serum albumin level < 30 g/L is the predictor for develop-
ing OHE in CHE patients [66]. In a study of Thomsen et al., that enrolled 106 clini-
cally stable cirrhotic patients with no previous history of OHE and followed them 
for 230 ± 95 d, it was found that, 13.3% of CHE patients developed OHE [67]. In a 
multicenter study by Patidar et al., a total of 170 cirrhotic patients were followed for 
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a mean of 13 months. They found that 30% of cirrhotic patients developed at least 
one OHE episode, and that CHE increased their risk of developing OHE, hospital-
ization, and death/transplant [36].
6. Diagnosis of MHE and CHE
There is no single optimal measure for diagnosis of MHE because none of the 
diagnostic strategies covers all aspects of deficits that are present in MHE [68, 69]. 
Testing approaches can be divided into two major types: psychometric and neu-
rophysiological [70, 71]. As MHE affects many elements of cognitive functioning, 
which may not be impaired to identical degrees, the International Society for Hepatic 
Encephalopathy and Nitrogen Metabolism (ISHEN) recommends the use of at least 
two tests, based on the local population norms and availability, and if possible, with 
one of the tests being more widely accepted to serve as a comparator [72].
6.1 Diseases associated with minimal hepatic encephalopathy
The diagnosis requires the indication of tests in subjects who appear normal, 
but may suffer from cirrhosis, as the physician usually does not observe MHE [73]. 
Further group of patients who are not cirrhotic and may develop MHE are those 
with porto-systemic shunts of inborn origin or secondary to portal thrombosis. The 
available data of the neuropsychological characteristics of these patients indicate 
that cognitive abnormalities are indistinguishable from MHE [74].
6.2 Indications for testing
There is no consensus on patients to test for MHE. Some physicians recommend 
screening of all cirrhotic patients. However, testing should be completed in patients 
at risk (Table 2) for MHE such as, cirrhosis or porto-systemic shunts [5]. Special 
attention should be given to active drivers, patients handling heavy machines or 
reporting decline in work performance [75, 76].
6.3 Neuropsychological (paper-and-pencil) tests
The American Association for the Study of Liver Diseases (AASLD) and the 
European Association for the Study of the Liver recommended neurophysiological 
Patients at risk of accidents
• Risks at work, e.g., machine worker
• Driving accident within the past year
• Unprovoked falls
Patients who complain of cognitive symptoms
• Psychomotor performance: “I have difficulty in carrying out fine motor tasks.”
• Decreased attention: “I am frequent feelig of confused.”
• Poor memory: “I forget a lot”.
Patients with decline in work performance observed by relatives or colleagues
Patients with previous history of episodic HE
Table 2. 
Patients with cirrhosis, portal vein thrombosis, or porto-systemic shunts who should undergo tests for MHE.
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Test Tested domain Time 
required 
(minuets)
Advantages Disadvantages Impact factor
NCT-A Psychomotor 
speed
1–2 Gold standard for MHE 
diagnosis validated 
internationally
Learning effects Age and culture
NCT-B Psychomotor 
speed, set 
shifting, 
divided 
attention
1–3 Validated 
internationally
Learning effects Age and culture
DST Psychomotor 
speed, attention
4 Very sensitive and is an 
early indicator
Learning effects Age and culture
BDT Visuospatial 
reasoning, praxis, 
psychomotor 
speed
10–20 It can be used for 
dementia testing as well
Learning effects Age and culture
SDT Psychomotor 
speed
1–2 Only tests psychomotor 
speed, a higher sensitivity
Learning effects; only 
tests psychomotor speed
Age and culture
LTT Psychomotor 
speed, 
visuomotor 
ability
2–4 Tests a balance between 
speed and accuracy
Learning effects,
outcomes are errors 
and time
Age and culture
Animal-
naming 
test
Semantic 
fluency test, 
verbal retrieval 
and recall
1 Easy test that has the 
required characteristics 
of simplicity, speed, for 
illiterate patients
Less validated test
CFF Visual 
discrimination 
and general 
arousal
10 Easy administration, 
application by a non-
specialist, and results are 
independent of literacy 
and age, test can be 
administered at bedside
Not suitable for 
red-green blindness and 
visual impairment
Age
ICT Response 
inhibition, 
working 
memory, 
vigilance, 
attention
15–20 Simple administration, 
higher sensitivity/
specificity
Need highly functional 
patients, not suitable for 
non-English-speaking 
patients
Age and 
education
Stroop test Psychomotor 
speed and 
cognitive 
alertness
10 Quick to explain to 
patients, and simple to 
score and evaluate
Should be familiar with 
iPhone/iPad
Age and 
education
The SCAN 
Test
Working 
memory, 
vigilance, 
attention
15–20 Simple administration Learning effects Age and 
education
CDR 
assessment 
battery
Reaction time, 
memory, and 
recognition
15 Appreciable test-retest 
reliability
Learning effects Age, education, 
and culture
EEG Generalized 
brain activity
10–15 Can be done in comatose 
patients, no need of 
patient cooperation or 
risk of a learning effect
Nonspecific and 
may be influenced 
by accompanying 
metabolic disturbances
Requires 
neurological 
expertise in 
evaluation
Table 3. 
Psychometric tests recommended for diagnosing minimal hepatic encephalopathy.
9Minimal Hepatic Encephalopathy: Silent Tragedy
DOI: http://dx.doi.org/10.5772/intechopen.88231
and psychometric tests to diagnose MHE [3, 51]. Many tests are used for diagnosis 
of MHE (Table 3); however, the gold standard and the most frequently used 
psychometric test for MHE diagnosis is psychometric hepatic encephalopathy score 
(PHES) [3, 4, 42].
6.3.1 Standard neuropsychological assessment
Neuropsychological testing is a useful methodology for quantifying cognitive 
impairment. These tests directly measure cognitive functions that are directly related 
to activities of daily living. These include the number connection test A (NCT-A), 
number connection test B (NCT-B), figure connection test (FCT A), figure connec-
tion test B (FCT B), digit symbol test (DST), and serial-dotting test (SDOT) [77].
6.3.1.1 Number connection tests
The NCT-A accesses the visual-spatial orientation and psychomotor speed. 
Twenty-five circles numbered from 1 to 25 are scattered randomly on a sheet of 
paper. The patients must connect the numbers in order in the shortest time possible 
without mistakes. If a mistake is made, the subject must stop, correct the error, 
and then continue without stopping the clock. The test score is the time needed to 
perform the test, including the time needed to correct all errors. Poorer performance 
is shown by a longer time for completion (Figure 3). In the NCT-B (Figure 4), the 
numbers from 1 to 13 and the letters from A to L were included in circles. The patient 
is asked to connect numbers and letters in alternating manner, that means go from 
1-A-2-B-3-C and so on. Test outcome is the time needed by the patient to perform the 
test, including error correction time. Besides visuospatial orientation and psychomo-
tor speed, this test is suitable to study the ability to shift attention [78].
According to the guidelines of the International Society for Hepatic 
Encephalopathy and Nitrogen Metabolism [79], the results of NCT-A will be consid-
ered abnormal when the test scores are more than the mean + 2 standard deviations 
(SDs) from the age-matched normal values. A newly developed electronic number 
connection test (eNCT) was developed. This test flashes the numbers 1–25 on a 
screen and needs the participant to click them in order while being timed [80]. 
These tests are time-consuming, and their results are influenced by age and educa-
tional status. However, these tests are recommended for diagnosis of MHE [42, 81].
Figure 3. 
Number connection tests-A.
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Figure 4. 
Number connection tests-B.
6.3.1.2 Digit symbol test DST
Nine fixed pairs of numbers and symbols are present at the top of the test sheet. 
The patient is given a series of double boxes with a number given in the upper 
part. The target is to draw a symbol related to this number into the lower part of 
the boxes. The test result is the number of boxes correctly filled in 90 s (Figure 5). 
Pathological test results indicate a deficit in visuoconstructive abilities. [82]. DST 
will be considered abnormal when the test scores are less than the mean − 2 SDs 
from the age-matched normal values [79].
6.3.1.3 Block design test
This test recorded speed and accuracy. The task is to take 6–9 blocks that have 
all white sides, all red sides, and red-and-white sides followed by arranging them 
according to a pattern formed by examiner or shown on a card [83].
6.3.1.4 Psychometric hepatic encephalopathy score (PHES)
It consists of five paper-pencil tests: NCT-A/B, line tracing time (LTT), digit 
symbol test, and serial-dotting test (SDOT). This battery measures psychomo-
tor speed and precision, visual perception, visuospatial orientation, visual 
Figure 5. 
Digit symbol test.
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construction, concentration, attention, and memory and can be completed in less 
than 20 minutes [68]. The results of PHES can be affected by age and education 
status of patients. A score is defined as the number of standard deviations of the 
difference between the two values for each test. MHE was diagnosed with the sum 
of all scores less than or equal to −4 points. Score < −4 suggests the presence of 
MHE [1, 84]. A simplified form of PHES, developed using only three of the original 
five tests, can be as good as the PHES in diagnosing [84]. For illiterate patients, the 
figure connection test has been used as a subtest instead of the number connection 
test [1]. PHES has a prognostic value for the occurrence of attacks of overt HE and 
mortality in cirrhotic patients [42, 43].
6.3.1.5 The animal naming test (ANT)
The ANT (maximum number of animals listed in 1 minute) has recently been 
developed to predict OHE. ANT is an easy test that has all the required character-
istics of simplicity, speed, no cost, and relationship with clinical events to be used 
routinely for rapid investigation of HE in patients with cirrhosis at the office and at 
the bedside [85].
6.3.2 Computer-aided psychometric tests
Numerous current studies have showed that, computerization of psychometric 
tests could lead to simplification and easy administration in the clinic within a few 
minutes [10, 86, 87].
6.3.2.1 The critical flicker frequency (CFF)
CFF test is a psychophysiological tool that studies the frequency at which a fused 
light (presented from 60 Hz downward) appears to be flickering to the observer. 
Similarly, the general arousal of the patient is measured. Earlier studies have shown 
a reduction in its performance with worsening cognition and improvement after 
therapy. The CFF test needs numerous trials, intact binocular vision, absence of 
red-green blindness, and specialized equipment [15]. CFF predicts the first epi-
sode of OHE in cirrhotic patients who had never experienced OHE, and predicts 
mortality risk [88]. CFF test has many advantages, for example, easy administra-
tion, application by a non-specialist personal, and results that are independent of 
numeracy, literacy, and age [89].
6.3.2.2 Continuous reaction time (CRT) test
This test assesses the motor reaction time by having the patient press a button 
in response to auditory stimuli (through headphones). The most important test 
result is the CRT index, which measures the stability of the reaction times. The 
test result can differentiate between organic and metabolic brain impairment. 
The test is not affected by the patient’s age, gender with no learning or tiring 
impact [90, 91].
6.3.2.3 The inhibitory control test (ICT)
It is a computerized test of response inhibition and working. The ICT requires 
highly functional patients (Figure 6). The ICT can be done using a laptop and is 
analyzed using an automatic computerized system that significantly improves the 
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convenience and flexibility of using this test in the clinical situation [92]. It has been 
validated for the diagnosis and follow-up of MHE in the USA. It was found that 
the ICT is simple to administer and has higher sensitivity/specificity for screening 
MHE than the standard psychometric test (SPT). On the other side, Taneja et al. 
found that the ICT is not as useful as the PHES in diagnosing MHE in patients with 
cirrhosis [93].
6.3.2.4 The Stroop test
In 2013, Bajaj et al. developed an application, the EncephalApp-Stroop App, for 
screening MHE that is operated by the iOS system on the iPhone and iPad. The core 
of this innovative application is the Stroop test, which assesses psychomotor speed 
and cognitive alertness by measuring the time required to correctly identify a series 
of symbols and printed words with different colors [86]. The Stroop test evaluates 
psychomotor speed and cognitive flexibility by the interference between recogni-
tion reaction time to a colored field and a written color name. [86]. In a multicenter 
study that compared the EncephalApp-Stroop App to the PHES and ICT, the 
EncephalApp-Stroop App had good sensitivity (70–80%) for MHE screening and 
was predictive of the progression to OHE [94].
6.3.2.5 The SCAN test
It is a computerized test that measures the patient’s speed and accuracy to per-
form a digit recognition memory task of increasing complexity [40, 95]. It is done 
by randomly displaying a series of 72 sorted pairs of numbers for 3 s on a computer 
screen. Patients are instructed to press the appropriate number on a keyboard if 
they identify a common digit in the sequence of numbers presented. The mean reac-
tion times and the percentage of errors are recorded, and the results are evaluated 
using the reaction times weighted by the number of errors [96].
Figure 6. 
Inhibitory control test. A continuous sequence of letters is displayed on the computer screen every 500 ms. The 
patient is educated to respond only if an X is preceded by a Y, or a Y is preceded by an X, but responses must be 
inhibited if an X is followed by an X, or a Y is followed by a Y.
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6.3.2.6 Cognitive drug research (CDR) assessment battery
It is a computerized battery of cognitive tests designed by the Cognitive Drug 
Research Ltd. (Goring-on-Thames, UK). The test contains five psychometric 
subsets that test attention power, attention continuity, speed of memory, and 
quality of episodic and working memory. It measures reaction time, memory, 
and recognition. The task stimuli are existing on a laptop, and patients pro-
vide the correct response using the “YES” and “NO” buttons on a two-button 
response box, which records both accuracy and reaction time. The sensitivity and 
specificity of the CDR assessment battery for screening MHE are 86.4 and 81%, 
respectively [10].
6.3.3 Electroencephalography examination (EEG)
EEG can discover changes in cortical cerebral activity across the spectrum of HE 
without patient cooperation or risk of a learning effect [97]. Newly, an-economy 
friendly device has been found to produce similar results compared with a standard 
EEG machine across the HE spectrum [97].
7. Treatment
Treatment of minimal hepatic encephalopathy with lactulose, probiotics, or 
l-ornithine-l-aspartate was seen to be effective in reducing abnormal tests and 
delay or eradicating risky motor car accident [47, 98–103]. It is therefore rational, 
especially if the patients or their family/caregivers report symptoms/signs compat-
ible with MHE, to introduce treatment specially in patients who are at particular 
risk of the consequences of MHE, such as falls, impaired, and driving ability.
7.1 Rifaximin
Rifaximin is an orally administered, non-absorbable, semi-synthetic antibiotic 
with a broad spectrum of effect on both Gram-positive and Gram-negative bacte-
ria [11, , 104]. It was found that patients with MHE treated with rifaximin for an 
8-week period showed significantly greater improvements in driving and cognitive 
performance and in the psychosocial dimension of the Sickness Impact Profile than 
those given a placebo [67]. Recently, a randomized controlled trial compared the 
efficacy of rifaximin with lactulose in reversal of MHE and improvement in HRQoL 
in cirrhotic patients with MHE. The study concluded that both drugs improve 
HRQoL equally well, in cirrhotic patients with MHE [105].
7.2 Non-absorbable disaccharides
The recommended standard of care for people with hepatic encephalopathy 
includes use of the non-absorbable disaccharides (lactulose and lactitol) [106, 107]. 
It was found that cirrhotic patients with MHE had improvement in health-related 
quality of life and psychometric performance after lactulose therapy [108]. Lactulose 
and lactitol, both, have effects on gut flora and are regarded as intestinal prebiotics. 
Adding lactulose to food can produce a bifidogenic effect connected to a favorable 
effect on colonic ammonia metabolism [109]. However, a recent meta-analysis 
evaluating the role of non-absorbable disaccharides in patients with MHE failed to 
show clear evidence in improving cognitive function and HRQoL [110].
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7.3 LOLA (l-ornithine-l-aspartate)
Ammonia scavengers, including l-ornithine-l-aspartate, are agents that reduce 
blood ammonia concentration by enhancing the metabolism of ammonia to gluta-
mine [111–113]. Bai et al. assessed eight RCTs (646 total patients, 46% diagnosed 
with MHE), evaluating the efficacy of LOLA compared to placebo in patients 
with cirrhosis. He found that treatment with LOLA diminished serum ammonia 
levels [114]. Evidence of important benefit of LOLA was also described in RCTs of 
patients with MHE assessed by psychometric testing or critical flicker frequency 
analysis. The oral formulation of LOLA was determined to be particularly effective 
for the treatment of OHE or MHE [115].
7.4 Probiotics
Prebiotics are non-digestible food ingredients that selectively stimulate the 
growth and/or activity of the bacteria in the colon. Probiotics are live microbes 
that alter the intestinal balance of the microflora. The combination of prebiotics 
and probiotics is named synbiotics. The meta-analysis of nine studies showed 
substantial evidence for the efficacy of prebiotics, probiotics, and synbiotics in the 
treatment of MHE [116]. A Cochrane Review examining the use of probiotics in the 
treatment of HE included seven trials and presented an advantage of probiotics to 
no treatment in all-cause mortality, number of adverse events, and QoL. Findings 
included reduced plasma concentrations of ammonia [117].
7.5 Zinc
Zinc, considered as a cofactor of urea cycle enzymes, is deficient in patients with 
cirrhosis, especially with malnutrition or encephalopathy [118]. Zinc is essential for 
the synthesis of coenzymes that mediate biogenic amine synthesis and metabolism 
[14]. Zinc deficiency also leads to change of neurotransmitters like γ aminobutyric 
acid and norepinephrine [119]. A recent RCT revealed that zinc supplementa-
tion can improve MHE in patients with liver cirrhosis associated with significant 
improvement in neuropsychometric tests and significantly decreased arterial 
ammonia level [76].
8. Conclusion
The prevalence of MHE is high in liver cirrhosis. MHE is characterized by subtle 
motor and cognitive deficits, and impairs health-related quality of life. Detection of 
MHE and subsequent treatment could substantially reduce societal costs by pre-
venting motor vehicle accident.
Conflict of interest
The authors declare that there is no conflict of interest.
Funding
This research received no specific grant from any funding agency in the public, 
commercial, or not for-profit sectors.
15
Minimal Hepatic Encephalopathy: Silent Tragedy
DOI: http://dx.doi.org/10.5772/intechopen.88231
Author details
Gamal Shiha1,2 and Nasser Mousa3*
1 Internal Medicine Department, Mansoura University, Egypt
2 Egyptian Liver Research Institute and Hospital (ELRIH), El-Mansoura, Egypt
3 Tropical Medicine Department, Mansoura University, Egypt
*Address all correspondence to: mousa_medic@yahoo.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
Liver Disease and Surgery
[1] Mullen KD, Prakash RK. New 
perspectives in hepatic encephalopathy. 
Clinics in Liver Disease. 2012;16:1-5
[2] Romero-Gómez M, Boza F, 
García-Valdecasas MS, García E, 
Aguilar-Reina J. Subclinical hepatic 
encephalopathy predicts the 
development of overt hepatic 
encephalopathy. The American Journal 
of Gastroenterology. 2001;96:2718-2723
[3] Vilstrup H, Amodio P, Bajaj J, 
Cordoba J, Ferenci P, Mullen KD, et al. 
Hepatic encephalopathy in chronic liver 
disease: 2014 Practice Guideline by the 
American Association for the Study 
of Liver Diseases and the European 
Association for the Study of the Liver. 
Hepatology. 2014;60:715-735
[4] Ferenci P, Lockwood A, Mullen K, 
Tarter R, Weissenborn K, Blei AT. 
Hepatic encephalopathy definition, 
nomenclature, diagnosis, and 
quantification: Final report of the 
working party at the 11th World 
Congresses of Gastroenterology, Vienna, 
1998. Hepatology. 2002;35:716-721
[5] Labenz C, Worns MA, 
Schattenberg JM, Huber Y, Galle PR, 
Labenz J, et al. Epidemiology of hepatic 
encephalopathy in german hospitals—
The EpHE study. Zeitschrift für 
Gastroenterologie. 2017;55:741-747
[6] Dhiman RK, Chawla YK. Minimal 
hepatic encephalopathy. Indian Journal 
of Gastroenterology. 2009;28(1):5-16
[7] Bajaj JS, Heuman DM, Bell DE, 
White M, Gilles H, Luketic VA, et al. 
Burden of cirrhosis and hepatic 
encephalopathy on patients and 
caregivers. Hepatology. 2010;410A:52
[8] Das A, Dhiman RK, Saraswat VA, 
Verma M, Naik SR. Prevalence and 
natural history of subclinical hepatic 
encephalopathy in cirrhosis. Journal 
of Gastroenterology and Hepatology. 
2001;16:531-535
[9] Waghray A, Waghray N, Mullen K. 
Management of covert hepatic 
encephalopathy. Journal of Clinical 
and Experimental Hepatology. 
2015;5:S75-S81
[10] Bajaj JS, Saeian K, Verber MD, 
Hischke D, Hoffmann RG, Franco J, 
et al. Inhibitory control test is a simple 
method to diagnose minimal hepatic 
encephalopathy and predict 
development of overt hepatic 
encephalopathy. The American Journal 
of Gastroenterology. 2007;102:754-760
[11] Ford JM, Gray M, Whitfield SL, 
Turken AU, Glover G, Faustman WO, 
et al. Acquiring and inhibiting prepotent 
responses in schizophrenia: Event-
related brain potentials and functional 
magnetic resonance imaging. Archives 
of General Psychiatry. 2004;61:119-129
[12] Bajaj JS. Management options 
for minimal hepatic encephalopathy. 
Expert Review of Gastroenterology & 
Hepatology. 2008;2:785-790
[13] Schomerus H, Hamster W. Quality 
of life in cirrhotic with minimal hepatic 
encephalopathy. Metabolic Brain 
Disease. 2001;16:37-41
[14] Sharma P, Sharma BC, Puri V, 
Sarin SK. Critical flicker frequency: 
Diagnostic tool for minimal hepatic 
encephalopathy. Journal of Hepatology. 
2007;47:67-73
[15] Romero-Gómez M, Córdoba J, 
Jover R, del Olmo JA, Ramírez M, 
Rey R, et al. Value of the critical flicker 
frequency in patients with minimal 
hepatic encephalopathy. Hepatology. 
2007;45:879-885
[16] Cordoba J, Alonso J, Rovira A, 
Jacas C, Sanpedro F, Castells L, et al. 
References
17
Minimal Hepatic Encephalopathy: Silent Tragedy
DOI: http://dx.doi.org/10.5772/intechopen.88231
The development of low-grade cerebral 
edema in cirrhosis is supported by 
the evolution of (1) H-magnetic 
resonance abnormalities after liver 
transplantation. Journal of Hepatology. 
2001;35:598-604
[17] Tapper EB, Jiang ZG, 
Patwardhan VR. Refining the ammonia 
hypothesis: A physiology-driven 
approach to the treatment of hepatic 
encephalopathy. Mayo Clinic 
Proceedings. 2015;90:646-658
[18] Patidar KR, Bajaj JS. Covert 
and overt hepatic encephalopathy: 
Diagnosis and management. Clinical 
Gastroenterology and Hepatology. 
2015;13(12):2048-2061
[19] Brusilow SW. Hyperammonemic 
encephalopathy. Medicine (Baltimore). 
2002;81(3):240-249
[20] Chatauret N, Butterworth RF. 
Effects of liver failure on inter-organ 
trafficking of ammonia: Implications 
for the treatment of hepatic 
encephalopathy. Journal of 
Gastroenterology and Hepatology. 
2004;19:S219-S223
[21] Cichoż-Lach H, Michalak A. Current 
pathogenetic aspects of hepatic 
encephalopathy and non cirrhotic 
hyperammonemic encephalopathy. 
World Journal of Gastroenterology. 
2013;19:26-34
[22] Cooper AJ, Plum F. Biochemistry 
and physiology of brain 
ammonia. Physiological Reviews. 
1987;67:440-519
[23] Wijdicks EF. Hepatic 
encephalopathy. The New England 
Journal of Medicine. 2016;375: 
1660-1670
[24] Schomerus H, Hamster W. 
Neuropsychological aspects of portal-
systemic encephalopathy. Metabolic 
Brain Disease. 1998;13:361-377
[25] Szerb JC, Butterworth RF. Effect 
of ammonium ions on synaptic 
transmission in the mammalian 
central nervous system. Progress in 
Neurobiology. 1992;39:135-153
[26] Luo M, Guo JY, Cao WK. 
Inflammation: A novel target of 
current therapies for hepatic 
encephalopathy in liver cirrhosis. 
World Journal of Gastroenterology. 
2015;21(41):11815-11824
[27] Shawcross DL, Davies NA, 
Williams R, Jalan R. Systemic 
inflammatory response exacerbates the 
neuropsychological effects of induced 
hyperammonemia in cirrhosis. Journal 
of Hepatology. 2004;40:247-254
[28] Shawcross DL, Wright G, Olde 
Damink SW, Jalan R. Role of ammonia 
and inflammation in minimal hepatic 
encephalopathy. Metabolic Brain 
Disease. 2007;22:125-138
[29] Aldridgea DR, Tranaha EJ, 
Shawcross DL. Pathogenesis of hepatic 
encephalopathy: Role of ammonia and 
systemic inflammation. Journal of 
Clinical and Experimental Hepatology. 
2015;5:S7-S20
[30] Seyan AS, Hughes RD, Shawcross DL. 
Changing face of hepatic encephalopathy: 
Role of inflammation and oxidative 
stress. World Journal of Gastroenterology. 
2010;16:3347-3357
[31] Bémeur C, Butterworth R. Liver-
brain proinflammatory signalling 
in acute liver failure: Role in the 
pathogenesis of hepatic encephalopathy 
and brain edema. Metabolic Brain 
Disease. 2013;28:145-150
[32] Schnabl B, Brenner DA. Interactions 
between the intestinal microbiome 
and liver diseases. Gastroenterology. 
2014;146(6):1513-1524
[33] Bajaj JS, Betrapally NS, 
Hylemon PB, Heuman DM, Daita K, 
Liver Disease and Surgery
18
White MB, et al. Salivary microbiota 
reflects changes in gut microbiota in 
cirrhosis with hepatic encephalopathy. 
Hepatology. 2015;62(4):1260-1271
[34] Zhang Z, Zhai H, Geng J, Yu R, 
Ren H, Fan H, et al. Large-scale survey 
of gut microbiota associated with MHE 
via 16S rRNA-based pyrosequencing. 
The American Journal of 
Gastroenterology. 2013;108:1601-1611
[35] Bajaj JS, Heuman DM, Hylemon PB, 
et al. Altered profile of human gut 
microbiome is associated with cirrhosis 
and its complications. Journal of 
Hepatology. 2014;60(5):940-947
[36] Patidar KR, Thacker LR, Wade JB, 
et al. Covert hepatic encephalopathy 
is independently associated with 
poor survival and increased risk 
of hospitalization. The American 
Journal of Gastroenterology. 
2014;109:1757-1763
[37] Hartmann IJ, Groeneweg M, 
Quero JC, Beijeman SJ, de 
Man RA, Hop WC, et al. The prognostic 
significance of subclinical hepatic 
encephalopathy. The American 
Journal of Gastroenterology. 
2000;95(8):2029-2034
[38] Das A, Dhiman RK, Saraswat VA, 
Verma M, Naik SR. Prevalence and 
natural history of subclinical hepatic 
encephalopathy incirrhosis. Journal 
of Gastroenterology and Hepatology. 
2001;16:531-533
[39] Lockwood AH. “What’s in a name?” 
improving the care of cirrhotics. Journal 
of Hepatology. 2000;32:859-861
[40] Amodio P, del Piccolo F,  
Marchetti P, Angeli P, Iemmolo R, 
Caregaro L, et al. Clinical features 
and survival of cirrhotic patients 
with subclinical cognitive alterations 
detected by the number connection test 
and computerized psychometric tests. 
Hepatology. 1999;29:1662-1667
[41] Romero-Gómez M, Grande L, 
Camacho I, Benitez S, Irles JA, 
Castro M. Altered response to oral 
glutamine challenge as prognostic 
factor for overt episodes in 
patients with minimal hepatic 
encephalopathy. Journal of Hepatology. 
2002;37(6):781-787
[42] Dhiman RK, Kurmi R, 
Thumburu KK, Venkataramarao SH, 
Agarwal R, Duseja A, et al. Diagnosis 
and prognostic significance of minimal 
hepatic encephalopathy inpatients with 
cirrhosis of liver. Digestive Diseases and 
Sciences. 2010;55(8):2381-2390
[43] Romero-Gómez M, Córdoba J, 
Jover R, et al. Value of the critica flicker 
frequency in patients with minimal 
hepatic encephalopathy. Hepatology. 
2007;45:879-885
[44] Wein C, Koch H, Popp B, 
Oehler G, Schauder P. Minimal hepatic 
encephalopathy impairs fitness to drive. 
Hepatology. 2004;39:739-745
[45] Watanabe A, Tuchida T, Yata Y, 
Kuwabara Y. Evaluation of 
neuropsychological function 
inpatients with liver cirrhosis with 
special reference to their driving 
ability. Metabolic Brain Disease. 
1995;10:239-248
[46] Bajaj JS, Hafeezullah M, 
Hoffmann RG, Varma RR, Franco J, 
Binion DG, et al. Navigation skill 
impairment: Another dimension of 
the driving difficulties in minimal 
hepaticencephalopathy. Hepatology. 
2008;47:596-604
[47] Dhiman RK, Sawhney MS, 
Chawla YK, Das G, Ram S, Dilawari JB. 
Efficacy of lactulose in cirrhotic patients 
with subclinical hepatic encephalopathy. 
Digestive Diseases and Sciences. 
2000;45:1549-1552
[48] Groeneweg M, Quero JC, De 
Bruijn I, Hartmann IJ, Essink-bot 
19
Minimal Hepatic Encephalopathy: Silent Tragedy
DOI: http://dx.doi.org/10.5772/intechopen.88231
ML, Hop WC, et al. Subclinical 
hepatic encephalopathy impairs daily 
functioning. Hepatology. 1998;28:45-49
[49] Roman E, Cordoba J, Torrens M, 
Torras X, Villanueva C, Vargas V, et al. 
Minimal hepatic encephalopathy is 
associated with falls. The American 
Journal of Gastroenterology. 
2011;106:476-482.49
[50] Zhou YQ , Chen SY, Jiang LD, 
Guo CY, Shen ZY, Huang PX, et al. 
Development and evaluation of the 
quality of life instrument in chronic 
liver disease patients with minimal 
hepatic encephalopathy. Journal of 
Gastroenterology and Hepatology. 
2009;24:408-415
[51] Bajaj JS, Etemadian A, 
Hafeezullah M, Saeian K. Testing for 
minimal hepatic encephalopathy in 
the United States: An AASLD survey. 
Hepatology. 2007;45:833-834
[52] Prasad S, Dhiman RK, Duseja A, 
Chawla YK, Sharma A, Agarwal R. 
Lactulose improves cognitive functions 
and health-relatedquality of life in 
patients with cirrhosis who have 
minimal hepaticencephalopathy. 
Hepatology. 2007;45:549-559
[53] Arguedas MR, DeLawrence TG, 
McGuire BM. Influence of hepatic 
encephalopathy on health-related 
quality of life in patients withcirrhosis. 
Digestive Diseases and Sciences. 
2003;48:1622-1626
[54] Bao ZJ, Qiu DK, Ma X, Fan ZP, 
Zhang GS, Huang YQ , et al. Assessment 
of health-related quality of life in 
Chinese patients with minimal hepatic 
encephalopathy. World Journal of 
Gastroenterology. 2007;13:3003-3008
[55] Sidhu SS, Goyal O, Mishra BP, 
Sood A, Chhina RS, Soni RK. Rifaximin 
improves psychometric performance 
and health-relatedquality of life 
in patients with minimal hepatic 
encephalopathy (the RIME Trial). The 
American Journal of Gastroenterology. 
2011;106:307-316
[56] Marchesini G, Bianchi G, Amodio P, 
Salerno F, Merli M, Panella C, et al. 
Italian Study Group for quality of life in 
cirrhosis. Factors associated with poor 
health-relatedquality of life of patients 
with cirrhosis. Gastroenterology. 
2001;120:170-178
[57] Arguedas MR, DeLawrence TG, 
McGuire BM. Influence of hepatic 
encephalopathy on health-related 
quality of life in patients with cirrhosis. 
Digestive Diseases and Sciences. 
2003;48:1622-1626
[58] Kim WR, Brown RS Jr, 
Terrault NA, El-Serag H. Burden of 
liver disease in the United States: 
Summary of a workshop. Hepatology. 
2002;36:227-242
[59] Qadri AM, Ogunwale BO, 
Mullen KD. Can we ignore minimal 
hepatic encephalopathy any longer? 
Hepatology. 2007;45:547-548
[60] Soriano G, Román E, Córdoba J, 
Torrens M, Poca M, Torras X, et al. 
Cognitive dysfunction in cirrhosis is 
associated with falls: A prospective 
study. Hepatology. 2012;55:1922-1930
[61] Urios A, Mangas-Losada A, 
Gimenez-Garzó C, González-López O, 
Giner-Durán R, Serra MA, et al. 
Altered postural control and stability 
in cirrhotic patients with minimal 
hepatic encephalopathy correlate with 
cognitive deficits. Liver International. 
2017;37:1013-1022
[62] Yildirim M. Falls in patients with 
liver cirrhosis. Gastroenterology 
Nursing. 2017;40(4):306-310
[63] Gad Y, Zaher A, Mousa N, 
El-desoky A, Al-Adarosy A. Screening 
for minimal hepatic encephalopathy 
in asymptomatic drivers with 
Liver Disease and Surgery
20
liver cirrhosis. Arab Journal of 
Gastroenterology. 2011;12(2):58-61
[64] Bajaj JS, Pinkerton SD, Sanyal AJ, 
Heuman DM. Diagnosis and treatment 
of minimal hepatic encephalopathy 
to prevent motor vehicle accidents: A 
cost-effectiveness analysis. Hepatology. 
2012;55:1164-1171
[65] Iwasa M, Sugimoto R, Mifuji- 
Moroka R, Hara N, Yoshikawa K, 
Tanaka H. Factors contributing to the 
development of overt encephalopathy in 
liver cirrhosis patients. Metabolic Brain 
Disease. 2016;31:1151-1156
[66] Wang AJ, Peng AP, Li BM, Gan N, 
Pei L, Zheng XL, et al. Natural history 
of covert hepatic encephalopathy: 
An observational study of 366 
cirrhotic patients. World Journal of 
Gastroenterology. 2017;23(34):6321-6329
[67] Thomsen KL, Macnaughtan J, 
Tritto G, Mookerjee RP, Jalan R. Clinical 
and pathophysiological characteristics 
of cirrhotic patients with grade 1 and 
minimal hepatic encephalopathy. PLoS 
One. 2016;11:e0146076
[68] Weissenborn K, Ennen JC, Schomerus H, 
Ruckert N, Hecker H. Neuropsychological 
characterization of hepatic 
encephalopathy. Journal of Hepatology. 
2001;34:768-773
[69] Weissenborn K, Giewekemeyer K, 
Heidenreich S, Bokemeyer M, 
Berding G, Ahl B. Attention, memory, 
and cognitive function in hepatic 
encephalopathy. Metabolic Brain 
Disease. 2005;20:359-367
[70] Montagnese S, Amodio P, 
Morgan MY. Methods for diagnosing 
hepatic encephalopathy in patients 
with cirrhosis: A multidimensional 
approach. Metabolic Brain Disease. 
2004;19:281-312
[71] Prakash R, Mullen KD. Mechanisms, 
diagnosis and management of hepatic 
encephalopathy. Nature Reviews. 
Gastroenterology & Hepatology. 
2010;7:515-525
[72] Guerit JM, Amantini A, Fischer C, 
Kaplan PW, Mecarelli O, Schnitzler A, 
et al. Neurophysiological investigations 
of hepatic encephalopathy: ISHEN 
practice guidelines. Liver International. 
2009;29:789-796
[73] Hilsabeck RC, Perry W, 
Hassanein TI. Neuropsychological 
impairment in patients with 
chronic hepatitis C. Hepatology. 
2002;35:440-446
[74] Ortiz M, Cordoba J, Alonso J, 
Rovira A, Quiroga S, Jacas C, et al. Oral 
glutamine challenge and magnetic 
resonance spectroscopy in three 
patients with congenital portosystemic 
shunts. Journal of Hepatology. 
2004;40:552-557
[75] Sharma P, Sharma BC, Puri V, 
Sarin SK. An open-label randomized 
controlled trial of lactulose and 
probiotics in the treatment of minimal 
hepatic encephalopathy. European 
Journal of Gastroenterology & 
Hepatology. 2008;20:506-511
[76] Mousa N, Abdel-Razik A, Zaher A, 
Hamed M, Shiha G, Effat N, et al. 
The role of antioxidants and zinc in 
minimal hepatic encephalopathy: A 
randomized trial. Therapeutic Advances 
in Gastroenterology. 2016;9(5):684-691
[77] Dhiman RK, Saraswat VA, 
Verma M, Naik SR. Figure connection 
test: A modified number connection 
test for the objective assessment of 
mental state in illiterates. Journal of 
Gastroenterology and Hepatology. 
1995;10:14-23
[78] Schomerus H, Hamster W. 
Neuropsychological aspects of 
portalsystemic encephalopathy. 
Metabolic Brain Disease. 
1998;13:361-377
21
Minimal Hepatic Encephalopathy: Silent Tragedy
DOI: http://dx.doi.org/10.5772/intechopen.88231
[79] Randolph C, Hilsabeck R, Kato A, 
Kharbanda P, Li YY, Mapelli D, et al. 
Neuropsychological assessment of 
hepatic encephalopathy: ISHEN 
practice guidelines. Liver International. 
2009;29(5):629-635
[80] Wuensch T, Ruether DF, Zöllner C, 
Mueller T, Jung T, Kaffarnik M, et al. 
Performance characterization of a novel 
electronic number connection test to 
detect minimal hepatic encephalopathy 
in cirrhotic patients. European Journal 
of Gastroenterology & Hepatology. 
2017;29(4):456-463
[81] Sharma P, Sharma BC, Puri V, 
Sarin SK. Natural history of minimal 
hepatic encephalopathy in patients 
with extrahepatic portal vein 
obstruction. The American Journal of 
Gastroenterology. 2009;104:885-890
[82] Kügler CF, Petter J, Taghavy A, 
Lotterer E, Wensing G, Hahn EG, 
et al. Dynamics of cognitive brain 
dysfunction in patients with 
cirrhotic liver disease: An event-
related P300 potential perspective. 
Electroencephalography and Clinical 
Neurophysiology. 1994;91:33-41
[83] Meyer T, Eshelman A, 
Abouljoud M. Neuropsychological 
changes in a large sample of liver 
transplant candidates. Transplantation 
Proceedings. 2006;38:3559-3660
[84] Riggio O, Ridola L, Pasquale C, 
Pentassuglio I, Nardelli S, 
Moscucci F, et al. A simplified 
psychometric evaluation for the 
diagnosis of minimal hepatic 
encephalopathy. Clinical 
Gastroenterology and Hepatology. 
2011;9:613-616.e1
[85] Campagna F, Montagnese S, 
Ridola L, Senzolo M, Schiff S, De 
Rui M, et al. The animal naming test: 
An easy tool for the assessment of 
hepatic encephalopathy. Hepatology. 
2017;66(1):198-208
[86] Bajaj JS, Thacker LR, Heumann DM, 
Fuchs M, Sterling RK, Sanyal AJ, et al. 
The Stroop smartphone application 
is a short and valid method to screen 
for minimal hepatic encephalopathy. 
Hepatology. 2013;58:1122-1132
[87] Mardini H, Saxby BK, Record CO. 
Computerized psychometric testing 
in minimal encephalopathy and 
modulation by nitrogen challenge and 
liver transplant. Gastroenterology. 
2008;135:1582-1590
[88] Barone M, Shahini E, Iannone A, 
Viggiani MT, Corvace V, et al. Critical 
flicker frequency test predicts overt 
hepatic encephalopathy and survival in 
patients with liver cirrhosis. Digestive 
and Liver Disease. 2018;50(5):496-500
[89] Coşkun B, Özen M. Critical flicker 
frequency test for diagnosing minimal 
hepatic encephalopathy in patients 
with cirrhosis. The Turkish Journal of 
Gastroenterology. 2017;28:191-196
[90] Lauridsen MM, Gronbaek H, 
Naeser EB, Leth ST, Vilstrup H. Gender 
and age effects on the continuous 
reaction times method in volunteers and 
patients with cirrhosis. Metabolic Brain 
Disease. 2012;27:559-565
[91] Lauridsen MM, Thiele M, Kimer N, 
Vilstrup H. The continuous reaction 
times method for diagnosing, grading, 
and monitoring minimal/covert hepatic 
encephalopathy. Metabolic Brain 
Disease. 2013;28:231-234
[92] Bajaj JS, Hafeezullah M, Franco J, 
Varma RR, Hoffmann RG, Knox JF, et al. 
Inhibitory control test for the diagnosis 
of minimal hepatic encephalopathy. 
Gastroenterology. 2008;135:1591-1600.
e1591
[93] Taneja S, Dhiman RK, Khatri A, 
Goyal S, Thumbru K, Agarwal R, et al. 
Inhibitory control test for the detection 
of minimal hepatic encephalopathy 
in patients with cirrhosis of liver. 
Liver Disease and Surgery
22
Journal of Clinical and Experimental 
Hepatology. 2012;2:306-314
[94] Allampati S, Duarte-Rojo A, 
Thacker LR, Patidar KR, White MB, 
Klair JS, et al. Diagnosis of minimal 
hepatic encephalopathy using 
Stroop EncephalApp: A multicenter 
US-based, norm-based study. The 
American Journal of Gastroenterology. 
2015;111:78-86
[95] Montagnese S, Schiff S, Turco M, 
Bonato CA, Ridola L, Gatta A, et al. 
Simple tools for complex syndromes: 
A three-level difficulty test for hepatic 
encephalopathy. Digestive and Liver 
Disease. 2012;44:957-960
[96] Amodio P, Marchetti P, Del 
Piccolo F, Rizzo C, Iemmolo RM, 
Caregaro L, et al. Study on the Sternberg 
paradigm in cirrhotic patients without 
overt hepatic encephalopathy. Metabolic 
Brain Disease. 1998;13:159-172
[97] Schiff S, Casa M, Di Caro V,  
Aprile D, Spinelli G, De Rui M,  
et al. A low-cost, user-friendly 
electroencephalographic recording 
system for the assessment of hepatic 
encephalopathy. Hepatology. 
2016;63(5):1651-1659
[98] Zucker DM, Redulla R. Lactulose 
management of minimal hepatic 
encephalopathy: A systematic 
review. Gastroenterology Nursing. 
2019;42(1):84-94
[99] Watanabe A, Sakai T, Sato S, 
Imai F, Ohto M, Arakawa Y, et al. 
Clinical efficacy of lactulose in cirrhotic 
patients with and without subclinical 
hepatic encephalopathy. Hepatology. 
1997;26(6):1410-1414
[100] Cao Q , Yu CB, Yang SG, Cao HC, 
Chen P, Deng M, et al. Effect of 
probiotic treatment on cirrhotic patients 
with minimal hepatic encephalopathy: 
A meta-analysis. Hepatobiliary  
& Pancreatic Diseases International.  
2018;17(1):9-16
[101] Gluud LL, Dam G, Les I, 
Marchesini G, Borre M, Aagaard NK, 
et al. Branched-chain amino acids for 
people with hepatic encephalopathy. 
Cochrane Database of Systematic 
Reviews. 2017;5:CD001939
[102] Horsmans Y, Solbreux PM, Daenens C, 
Desager JP, Geubel AP. Lactulose improves 
psychometric testing in cirrhotic 
patients with subclinical 
encephalopathy. Alimentary 
Pharmacology & Therapeutics. 
1997;11(1):165-170
[103] Sidhu SS, Goyal O, Mishra BP, 
Sood A, Chhina RS, Soni RK. Rifaxim 
improves psychometric performance 
and health-related quality of life 
in patients with minimal hepatic 
encephalopathy (the RIME Trial). The 
American Journal of Gastroenterology. 
2011;106(2):307-316
[104] Kimer N, Krag A, Gluud LL. Safety, 
efficacy, and patient acceptability of 
rifaximin for hepatic encephalopathy. 
Patient Preference and Adherence. 
2014;8:331
[105] Sidhu SS, Goyal O, Parker RA, 
Kishore H, Sood A. Rifaximin vs. 
lactulose in treatment of minimal 
hepatic encephalopathy. Liver 
International. 2016;36:378-385
[106] Johanson JF. Review of the 
treatment options for chronic 
constipation. Medscape General 
Medicine. 2007;9(2):25
[107] Jain L, Sharma BC, 
Srivastava S, Puri SK, Sharma P, 
Sarin S. Serum endotoxin, inflammatory 
mediators, and magnetic resonance 
spectroscopy before and after 
treatment in patients with minimal 
hepatic encephalopathy. Journal of 
Gastroenterology and Hepatology. 
2013;28:1187-1193
23
Minimal Hepatic Encephalopathy: Silent Tragedy
DOI: http://dx.doi.org/10.5772/intechopen.88231
[108] Prasad S, Dhiman RK, Duseja A, 
Chawla YK, Sharma A, Agarwal R, 
et al. Lactulose improves cognitive 
functions and health-related quality 
of life in patients with cirrhosis who 
have minimal hepatic encephallopathy. 
Hepatology. 2007;45(3):549-559
[109] Bouhnik Y, Attar A, Joly FA, 
Riottot M, Dyard F, Flourié B, et al. 
Lactulose ingestion increases Faecal 
bifidobacterial counts: A randomised 
double-blind study in healthy humans. 
European Journal of Clinical Nutrition. 
2004;58:462-466
[110] Gluud LL, Vilstrup H, Morgan MY. 
Non-absorbable disaccharides versus 
placebo/no intervention and lactulose 
versus lactitol for the prevention and 
treatment of hepatic encephalopathy 
in people with cirrhosis. Cochrane 
Database of Systematic Reviews. 
2016;5:CD003044
[111] Blanco Vela CI, Poo 
Ramirez JL. Efficacy of oral L-ornithine 
L-aspartate in cirrhotic patients 
with hyperammonemic hepatic 
encephalopathy. Annals of Hepatology. 
2011;10(Suppl 2):S55-S59
[112] Rahimi RS, Rockey DC. Hepatic 
encephalopathy: Pharmacological 
therapies targeting ammonia. Seminars 
in Liver Disease. 2016;36(1):48-55
[113] De Las Heras J, Aldamiz- 
Echevarria L, Martinez-Chantar ML, 
Delgado TC. An update on the use 
of benzoate, phenylacetate and 
phenylbutyrate ammonia scavengers 
for interrogating and modifying 
liver nitrogen metabolism and its 
implications in urea cycle disorders 
and liver disease. Expert Opinion 
on Drug Metabolism & Toxicology. 
2017;13(4):439-448
[114] Bai M, Yang Z, Qi X, Fan D, 
Han G. L-ornithine-L-aspartate for 
hepatic encephalopathy in patients 
with cirrhosis: A meta-analysis of 
randomized controlled trials. Journal 
of Gastroenterology and Hepatology. 
2013;28:783-792
[115] Butterworth RF, McPhail MJW. 
L-ornithine L-aspartate (LOLA) for 
hepatic encephalopathy in cirrhosis: 
Results of randomized controlled 
trials and meta-analyses. Drugs. 
2019;79(Suppl 1):31-37
[116] Shukla S, Shukla A, Mehboob S, 
Guha S. Meta-analysis: The effects of 
gut flora modulation using prebiotics, 
probiotics andsynbiotics on inimal 
hepatic encephalopathy. Alimentary 
Pharmacology & Therapeutics. 
2011;33:662-671
[117] McGee RG, Bakens A, Wiley K, 
et al. Probiotics for patients with hepatic 
encephalopathy. Cochrane Database of 
Systematic Reviews. 2011;11:CD008716
[118] Blei A, Córdoba J, Practice 
Parameters Committee of the American 
College of Gastroenterology. Hepatic 
encephalopathy. American Journal of 
Gastroenterology. 2001;96:1968-1976
[119] Chetri K, Choudhuri G. 
Role of trace elements in hepatic 
encephalopathy: Zinc and manganese. 
Indian Journal of Gastroenterology. 
2003;22(Suppl 2):S28-S30
